Literature DB >> 18926452

Effect of hospital volume on margin status after pancreaticoduodenectomy for cancer.

Karl Y Bilimoria1, Mark S Talamonti, Stephen F Sener, Malcolm M Bilimoria, Andrew K Stewart, David P Winchester, Clifford Y Ko, David J Bentrem.   

Abstract

BACKGROUND: The volume-outcome relationship has been repeatedly demonstrated for pancreatectomy, but identifying underlying reasons for this association has been challenging. Some have suggested that differences in surgical technique may affect longterm survival, but it is unknown whether margin-positive resection rates vary by hospital volume. Our objective was to evaluate the effect of hospital pancreatectomy volume on margin status. STUDY
DESIGN: Patients who underwent pancreaticoduodenectomy for localized pancreatic adenocarcinoma were identified from the National Cancer Data Base (1998 to 2004). Regression modeling adjusting for patient, tumor, and hospital factors was used to assess predictors of margin involvement and to evaluate the effect of margin status on survival. Volume quintiles were based on average annual hospital pancreatectomy volume.
RESULTS: Of 12,101 patients, 24.4% had positive resection margins (14.6% microscopic/R1; 9.8% macroscopic/R2). From 1998 to 2004, there was not a significant change in margin-positive resection rates (p=0.43). On multivariable analysis, patients were more likely to have a margin-positive resection if they had a higher T classification or nodal involvement, were uninsured or living in lower-income areas, or underwent resection at lowest-volume hospitals compared with highest-volume hospitals (25.9% versus 22.6%, p < 0.0001; odds ratio, 1.21; 95% confidence interval, 1.01 to 1.43). On multivariable analysis, margin involvement was associated with a higher risk of longterm mortality compared with margin-negative resections (p < 0.0001).
CONCLUSIONS: Involved resection margins are a poor prognostic factor after a pancreaticoduodenectomy. Patients undergoing pancreaticoduodenectomy at low-volume centers are more likely to have margin-positive resections. Standardization of pathologic evaluation for pancreatectomy specimens is needed.

Entities:  

Mesh:

Year:  2008        PMID: 18926452     DOI: 10.1016/j.jamcollsurg.2008.04.033

Source DB:  PubMed          Journal:  J Am Coll Surg        ISSN: 1072-7515            Impact factor:   6.113


  51 in total

1.  Potential contribution of preoperative neoadjuvant concurrent chemoradiation therapy on margin-negative resection in borderline resectable pancreatic cancer.

Authors:  Chang Moo Kang; Yong Eun Chung; Jeong Youp Park; Jin Sil Sung; Ho Kyoung Hwang; Hye Jin Choi; Hyunki Kim; Si Young Song; Woo Jung Lee
Journal:  J Gastrointest Surg       Date:  2011-12-20       Impact factor: 3.452

2.  Invasive intraductal papillary mucinous neoplasm: predictors of survival and role of adjuvant therapy.

Authors:  Olivier Turrini; Joshua A Waters; Thomas Schnelldorfer; Keith D Lillemoe; Constantin T Yiannoutsos; Michael B Farnell; Michael G Sarr; C Max Schmidt
Journal:  HPB (Oxford)       Date:  2010-09       Impact factor: 3.647

Review 3.  Borderline resectable pancreatic cancer: definitions and management.

Authors:  Nicole E Lopez; Cristina Prendergast; Andrew M Lowy
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

4.  Accomplishments in 2008 in the management of localized pancreatic cancer.

Authors:  Eileen M O'Reilly; Manfred P Lutz; Peter Neuhaus
Journal:  Gastrointest Cancer Res       Date:  2009-09

5.  Complete mesocolic excision--a marker of surgical quality?

Authors:  Aisling M Hogan; Des C Winter
Journal:  J Gastrointest Surg       Date:  2009-08-05       Impact factor: 3.452

6.  Rapid improvement of glucagonoma-related necrolytic migratory erythema with octreotide.

Authors:  Shiro Kimbara; Yutaka Fujiwara; Masanori Toyoda; Naoko Chayahara; Yoshinori Imamura; Naomi Kiyota; Toru Mukohara; Atsushi Fukunaga; Masahiro Oka; Chikako Nishigori; Hironobu Minami
Journal:  Clin J Gastroenterol       Date:  2014-04-09

7.  Pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: a French multicentre prospective evaluation of resection margins in 150 evaluable specimens.

Authors:  Jean Robert Delpero; Philippe Bachellier; Nicolas Regenet; Yves Patrice Le Treut; François Paye; Nicolas Carrere; Alain Sauvanet; Aurélie Autret; Olivier Turrini; Geneviève Monges-Ranchin; Jean Marie Boher
Journal:  HPB (Oxford)       Date:  2013-03-07       Impact factor: 3.647

8.  Institutional clinical trial accrual volume and survival of patients with head and neck cancer.

Authors:  Evan J Wuthrick; Qiang Zhang; Mitchell Machtay; David I Rosenthal; Phuc Felix Nguyen-Tan; André Fortin; Craig L Silverman; Adam Raben; Harold E Kim; Eric M Horwitz; Nancy E Read; Jonathan Harris; Qian Wu; Quynh-Thu Le; Maura L Gillison
Journal:  J Clin Oncol       Date:  2014-12-08       Impact factor: 44.544

9.  Favorable perioperative outcomes after resection of borderline resectable pancreatic cancer treated with neoadjuvant stereotactic radiation and chemotherapy compared with upfront pancreatectomy for resectable cancer.

Authors:  Eric A Mellon; Tobin J Strom; Sarah E Hoffe; Jessica M Frakes; Gregory M Springett; Pamela J Hodul; Mokenge P Malafa; Michael D Chuong; Ravi Shridhar
Journal:  J Gastrointest Oncol       Date:  2016-08

Review 10.  [Medical-oncological aspects in the treatment of pancreatic cancer].

Authors:  V Heinemann
Journal:  Radiologe       Date:  2009-02       Impact factor: 0.635

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.